Research Analysts Issue Forecasts for Climb Bio Q1 Earnings

Climb Bio, Inc. (NASDAQ:CLYM) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Climb Bio in a research report issued to clients and investors on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.26) per share for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Climb Bio’s Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.31) EPS and Q4 2027 earnings at ($0.32) EPS.

CLYM has been the subject of a number of other research reports. Wedbush started coverage on Climb Bio in a report on Thursday, March 5th. They issued an “outperform” rating and a $12.00 price objective for the company. Raymond James Financial initiated coverage on Climb Bio in a report on Tuesday. They set a “strong-buy” rating on the stock. Piper Sandler initiated coverage on Climb Bio in a research note on Friday, February 13th. They issued an “overweight” rating for the company. Robert W. Baird increased their price target on shares of Climb Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Climb Bio has an average rating of “Moderate Buy” and a consensus target price of $11.40.

Climb Bio Price Performance

Shares of NASDAQ:CLYM opened at $7.33 on Wednesday. The stock has a market cap of $499.79 million, a price-to-earnings ratio of -8.24 and a beta of -0.25. The company has a 50 day moving average of $5.39 and a 200-day moving average of $3.43. Climb Bio has a one year low of $1.05 and a one year high of $8.04.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06).

Institutional Trading of Climb Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MPM Bioimpact LLC acquired a new stake in Climb Bio in the 4th quarter valued at $10,686,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Climb Bio by 265.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock worth $7,695,000 after buying an additional 1,396,722 shares during the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Climb Bio by 972.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock valued at $5,730,000 after acquiring an additional 1,298,945 shares in the last quarter. Sphera Funds Management LTD. increased its position in shares of Climb Bio by 114.4% in the fourth quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock valued at $3,729,000 after acquiring an additional 497,410 shares during the last quarter. Finally, Diadema Partners LP increased its position in shares of Climb Bio by 4.8% in the second quarter. Diadema Partners LP now owns 702,135 shares of the company’s stock valued at $871,000 after acquiring an additional 32,332 shares during the last quarter. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Climb Bio

In related news, Director Ra Capital Management, L.P. purchased 101,462 shares of Climb Bio stock in a transaction dated Friday, December 12th. The stock was bought at an average price of $2.86 per share, for a total transaction of $290,181.32. Following the completion of the acquisition, the director directly owned 3,396,318 shares of the company’s stock, valued at $9,713,469.48. This represents a 3.08% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.80% of the company’s stock.

Key Stories Impacting Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: HC Wainwright raised its price target on CLYM from $11 to $15 and kept a “Buy” rating — a large upside vs. the current share price, which is likely the main bullish catalyst for the stock today. Benzinga Article
• Neutral Sentiment: HC Wainwright published quarterly EPS estimates for FY2027 (Q1: -$0.26, Q2: -$0.29, Q3: -$0.31, Q4: -$0.32) and a full‑year consensus of about -$1.57. These are model-driven projections that reaffirm expected losses but also provide a roadmap for investor expectations. MarketBeat Report
• Negative Sentiment: Reports flagged a “large increase” in March short interest, but the published figures show 0 shares and NaN changes with a 0.0 days-to-cover — indicating likely data/reporting errors. If confirmed as a real short build, it could add downward pressure; as-is, the ambiguity may fuel volatility and speculative trading.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.